Hiring in the Asia-Pacific pharma industry rise by 2% in Q1 2023

Notably, Management Occupations jobs accounted for a 20% share of the Asia-Pacific pharma industry’s total new job postings in Q1 2023, rise 20% over the prior quarter.

Management Occupations drive pharma hiring activity

Management Occupations, with a share of 20% new job postings, was the occupation with the greatest hiring activity in the Asia-Pacific pharma industry in Q1 2023 , ahead of Life, Physical, and Social Science Occupations with a 14% share of new job postings.

The other prominent roles included Healthcare Practitioners and Technical Occupations with a 7% share in Q1 2023, Computer and Mathematical Occupations with a 6% share and Business and Financial Operations Occupations with a 3% share of new job postings.

Top five companies accounted for 67% of hiring activity

Biocon posted 8,387 jobs in Q1 2023 and registered a growth of 198% over the previous quarter, followed by Novartis with 1,240 jobs and a 78% growth. Takeda Pharmaceutical, with 999 jobs, and Merck, with 983 jobs, recorded a 19% rise and an 18% drop, respectively, while Pfizer recorded a 64% decline with a 859 new job postings during Q1 2023.

Regional analysis of hiring in the Asia-Pacific pharma industry, Q1 2023

India held the leading share of the Asia-Pacific pharma hiring activity with a 62.85% share, a 53% increase over Q4 2022. China was next with 16.53%, four-percentage-point down over the previous quarter.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Jobs Analytics uses machine learning to uncover key insights from tracking daily job postings for thousands of companies globally. Proprietary analysis is used to group jobs into key thematic areas and granular sectors across the world’s largest industries. classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.